Center for Innovative Phage Applications and Therapeutics

Real-World Evidence and Data Analytics Conference (Frankfurt, Germany - October 5-6, 2023): Paving the Path for Next-Gen Medicinal Research

Retrieved on: 
Friday, September 29, 2023
Real-World Evidence, Real, VEO, Associate Director of National Intelligence and Chief Information Officer, Parameter, Big data, Pharmacovigilance, ML, Merck Group, Center for Innovative Phage Applications and Therapeutics, RWE, AI, Insight, Epidemiology, Conference, Data science, Fine chemical, Medical device, Pharmaceutical industry

DUBLIN, Sept. 29, 2023 /PRNewswire/ -- The "Real-World Evidence and Data Analytics Conference" set to take place on October 5th and 6th, 2023, in Frankfurt, Germany has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 29, 2023 /PRNewswire/ -- The "Real-World Evidence and Data Analytics Conference" set to take place on October 5th and 6th, 2023, in Frankfurt, Germany has been added to ResearchAndMarkets.com's offering.
  • Building on five triumphant installments held in Boston, USA, this year's European chapter promises an invigorating assembly of experts, leaders, and stakeholders.
  • The confluence aims to shed light on the accelerating evolution of real-world evidence (RWE) and its vital impact on drug benefit elucidation.
  • Its pivotal role in patient monitoring through digital platforms, coupled with aiding clinical data organization for regulatory inclusions, is noteworthy.

Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Retrieved on: 
Monday, June 12, 2023
Lymphoma, Hodgkin lymphoma, Lymphocyte, Senior, DCR, Sichuan University, Toxicity, Immunotherapy, Incidence, HKEX, HIV disease progression rates, Patient, Anemia, Ophthalmology, CEST, EHA, Hospital, European Society for Medical Oncology, PD-1, Death, PD-L1, ORR, Autoimmunity, Safety, Pharmaceutical industry, Palladium, Center for Innovative Phage Applications and Therapeutics

The EHA Annual Meeting was held in Frankfurt, Germany, from June 8 to 15, 2023.

Key Points: 
  • The EHA Annual Meeting was held in Frankfurt, Germany, from June 8 to 15, 2023.
  • Eligible patients receive IBI322 (45 mg/kg intravenous Q2W) until unacceptable toxicity or disease progression, or up to 24 months.
  • Overall, IBI322 monotherapy showed promising anti-tumor efficacy with a manageable safety profile in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin lymphoma patients.
  • IBI322 has the potential to be an effective treatment option for the treatment of immunotherapy-resistant classical Hodgkin lymphoma and other types of lymphoma to meet the unmet clinical needs. "

IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel（BCMA CAR-T Cell Therapy）for Multiple Myeloma at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Tongji Hospital station, DNA, Fragment crystallizable region, Pi, Biotechnology, SCR, CRS, Hook effect, DOR, B-cell maturation antigen, American Society of Clinical Oncology, Bone marrow, Huachung University, Cmax, Doctor of Philosophy, PFS, Trial of the century, MTTR, ASCO, MRD, CAR, Tongji Medical College, CR, Congress, Multiple myeloma, MD, Patient, Cytokine release syndrome, SAN, EMM, Annual general meeting, Immunotherapy, EHA, MM, RRMM, Huazhong University of Science and Technology, Proteasome inhibitor, Society, ADA, ORR, BCMA, Safety, Center for Innovative Phage Applications and Therapeutics, Disease, Vaccine, Pharmaceutical industry

The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.

Key Points: 
  • The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.
  • Among the 103 patients, 68.9% (71/103) had high-risk cytogenetic abnormalities per mSMART 3.0, 12.6%（13/103）had extramedullary multiple myeloma (EMM), and 11.7%（12/103）had received prior CAR-T therapy.
  • Equecabtagene Autoleucel demonstrated a favorable and manageable safety profile: Among the 103 patients, 93.2% (96/103) experienced cytokine release syndrome (CRS).
  • These results are encouraging and entails an opportunity to advance Equecabtagene Autoleucel to earlier lines of treatment to benefit more MM patients."

Insilico Medicine Appoints Sujata Rao, M.D., as Senior Vice President to Oversee Clinical Development

Retrieved on: 
Tuesday, July 19, 2022
Leadership, University, Insilico Medicine, Center for Innovative Phage Applications and Therapeutics, Memorial Sloan Kettering Cancer Center, History, Biology, CEO, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, University of Washington Department of Bioengineering, Patient, Cancer, Infection, Solution, Ramucirumab, Internal medicine, Inflammation, GLOBE, Fibrosis, Drug discovery, Program, Jacobs School of Medicine and Biomedical Sciences, Biomedical sciences, AI, Record, Onyx Pharmaceuticals, Chemistry, Bristol Myers Squibb, Eli Lilly and Company, Nivolumab, Peripheral nervous system, Drug development, Thyroid cancer, Associate, Industry, Liver, NDA, Eli Lilly, Senior, Lung cancer, SVP, Degenerative disease, Partnership, Intelligence, Sintilimab, Immunity, PD-1, Population, Medical device, Pharmaceutical industry, Interleukin 10, In silico, Medicine

New York, July 19, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as Senior Vice President (SVP) with responsibility for the global clinical development strategy of Insilico Medicine's therapeutic programs.

Key Points: 
  • New York, July 19, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as Senior Vice President (SVP) with responsibility for the global clinical development strategy of Insilico Medicine's therapeutic programs.
  • The unique opportunity at Insilico allows me to join a world class AI drug discovery team that can rapidly bring novel drugs to patients with a great unmet need, said Sujata Rao M.D., Senior Vice President, Head of Clinical Development at Insilico Medicine.
  • This is a transformative approach to drug development with shortened timelines that I hope will make a huge clinical impact.
  • Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.

Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022

Retrieved on: 
Monday, April 4, 2022
ACC, Congress, III, Autoimmunity, HKEX, Center for Innovative Phage Applications and Therapeutics, Safety, American College, AAC, R, SAN, Patient, Pharmaceutical industry

The AAC 2022 presentation is based on CREDIT-2, a randomized, double-blind, placebo-controlled phase 3 study, evaluating the efficacy and safety of IBI306 in Chinese patients with heterozygous familial hypercholesterolemia (ClinicalTrials.gov, NCT04179669).

Key Points: 
  • The AAC 2022 presentation is based on CREDIT-2, a randomized, double-blind, placebo-controlled phase 3 study, evaluating the efficacy and safety of IBI306 in Chinese patients with heterozygous familial hypercholesterolemia (ClinicalTrials.gov, NCT04179669).
  • The results of study showed that both IBI306 150 mg Q2W or 450 mg Q4W yielded significant reduction in LDL-C levels in Chinese patients with HeFH.
  • Results from the first completed CREDIT-2 phase 3 study have also been accepted and presented as a poster at the American Cardiology Association Annual Congress 2022 (ACC 2022).
  • The CREDIT-4 study was a randomized, double-blind, placebo-controlled phase 3 clinical study to assess the efficacy and safety of IBI306 in Chinese patients with hypercholesterolemia (including non-familial hypercholesterolemia and heterozygous familial hypercholesterolemia) (ClinicalTrials.gov, NCT04709536).

AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, March 1, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MD Anderson Cancer Center, Social conditions in Honduras, Crizotinib, CSCO, Annual general meeting, Therapy, BTD, HKEX, Company, CMC, AXL, Senior, Lung cancer, Stock exchange, ALT, Hereditary nonpolyposis colorectal cancer, Environment, Safety, Chinese, NMPA, Review, Center for Drug Evaluation and Research, Autoimmunity, Lung, NSCLC, Entrepreneurship, AST, Metabolism, Breakthrough therapy, CDE, Bevacizumab, DCR, Center, Trial of the century, Cancer, Eli Lilly and Company, ROS1, ORR, Integrity, Patient, Control, TKI, Clinical trial, Motherboard, Nature, News, Chemistry, Marketing, Large-cell lung carcinoma, MD, Pharmaceutical industry, Incyte, Glioblastoma, Cholangiocarcinoma, Center for Innovative Phage Applications and Therapeutics, Taletrectinib, AnHeart Therapeutics, Innovent, TALETRECTINIB, ANHEART THERAPEUTICS, INNOVENT

The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors.

Key Points: 
  • The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors.
  • "There is a high unmet medical need for lung cancer patients with ROS1 fusion mutations," said Bing Yan, MD, Co-Founder and Chief Medical Officer at AnHeart Therapeutics.
  • We are glad to see the NMPA grant Breakthrough Therapy Designation based on the Phase 2 data of taletrectinib, said Dr. Hui Zhou, Senior Vice President of Innovent.
  • Taletrectinib is a novel best-in-class next-generation ROS1 inhibitor designed to effectively target ROS1 fusion mutations with potential to treat both TKI-nave and pre-treated patients.

Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer

Retrieved on: 
Friday, July 30, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Biomedical Advanced Research and Development Authority, Bacteriophage, Articles, Life sciences, Organisms, Bacteriophages, Robert T. Schooley, Center for Innovative Phage Applications and Therapeutics, Pharmaceutical industry

Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has promoted Robert Hopkins, M.D., to Chief Medical Officer.

Key Points: 
  • Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has promoted Robert Hopkins, M.D., to Chief Medical Officer.
  • Dr. Robert Hopkins joined Adaptive Phage Therapeutics in 2019, after serving as Senior Medical Advisor in the Division of Clinical Services (DCS) for the Biomedical Advanced Research and Development Authority (BARDA) in Washington, D.C.
  • Combating infectious diseases presents a critical need that affects a large portion of the population, said Dr. Robert Hopkins.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

Global Bacteriophage Market Report 2021-2029: Increasing R&D is Expected to Multiply Revenues - Food & Beverages Display Highest Share - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Research, Infectious diseases, Clinical trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Bacteriophages, Articles, Branches of biology, Microbiology, Bacteriophage, Phage therapy, Center for Innovative Phage Applications and Therapeutics, Phage ecology

With increasing inpatient care there has been a rise in the adoption of bacteriophage in phage research centers, along with bacteriophage supplements.

Key Points: 
  • With increasing inpatient care there has been a rise in the adoption of bacteriophage in phage research centers, along with bacteriophage supplements.
  • Bacteriophage is also known as phage therapy and it needs viruses for the medication of bacterial infections.
  • Increasing government funding to support phage therapy manufacturers in developing an innovative approach to decrease antimicrobial-resistant infection cases is anticipated to boost market growth.
  • At present food & beverages occupy the largest revenue share in the global bacteriophage market.

Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank™ in Urinary Tract Infections

Retrieved on: 
Thursday, June 3, 2021
Health, Infectious diseases, Hospitals, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Bacteriophages, Life sciences, Health care, Phage therapy, Therapy, Bacteriophage, Multiple drug resistance, Pathogenic bacteria, Center for Innovative Phage Applications and Therapeutics, Robert T. Schooley

This multi-center clinical trial represents the first study of an expanding phage library for intravenous administration and/or bladder instillation of phage therapy.

Key Points: 
  • This multi-center clinical trial represents the first study of an expanding phage library for intravenous administration and/or bladder instillation of phage therapy.
  • PhageBank is APTs continually expanding phage library that functions as an integrated logistics platform to dispense phage on demand.
  • The PST enables rapid, automated identification of individual phage to be included in patient-specific therapy to treat bacterial infections.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

Adaptive Phage Therapeutics to Participate in the NobleCon17 Virtual Investor Conference

Retrieved on: 
Friday, January 15, 2021
Biotechnology, General Health, Infectious diseases, Health, Pharmaceutical, Bacteriophages, Bacteriophage, Biology, Articles, Life sciences, Health care, Center for Innovative Phage Applications and Therapeutics, Phage therapy

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company will participate in the 17th Annual Small & Microcap Investor Conference (NobleCon17) being organized by Noble Financial Group, taking place virtually on January 19-20, 2021.

Key Points: 
  • Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company will participate in the 17th Annual Small & Microcap Investor Conference (NobleCon17) being organized by Noble Financial Group, taking place virtually on January 19-20, 2021.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.
  • APTs PhageBank approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage.
  • PhageBank phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.